| pubmed-article:18544557 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18544557 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:18544557 | lifeskim:mentions | umls-concept:C0003968 | lld:lifeskim |
| pubmed-article:18544557 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:18544557 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:18544557 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:18544557 | pubmed:dateCreated | 2008-10-27 | lld:pubmed |
| pubmed-article:18544557 | pubmed:abstractText | Ascorbic acid is a widely used and controversial alternative cancer treatment. In millimolar concentrations, it is selectively cytotoxic to many cancer cell lines and has in vivo anticancer activity when administered alone or together with other agents. We carried out a dose-finding phase I and pharmacokinetic study of i.v. ascorbic acid in patients with advanced malignancies. | lld:pubmed |
| pubmed-article:18544557 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18544557 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18544557 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18544557 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18544557 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18544557 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18544557 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18544557 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:18544557 | pubmed:issn | 1569-8041 | lld:pubmed |
| pubmed-article:18544557 | pubmed:author | pubmed-author:LevineMM | lld:pubmed |
| pubmed-article:18544557 | pubmed:author | pubmed-author:RousseauCC | lld:pubmed |
| pubmed-article:18544557 | pubmed:author | pubmed-author:MillerW HWHJr | lld:pubmed |
| pubmed-article:18544557 | pubmed:author | pubmed-author:RobitailleLL | lld:pubmed |
| pubmed-article:18544557 | pubmed:author | pubmed-author:AssoulineSS | lld:pubmed |
| pubmed-article:18544557 | pubmed:author | pubmed-author:HofferL JLJ | lld:pubmed |
| pubmed-article:18544557 | pubmed:author | pubmed-author:MelnychukDD | lld:pubmed |
| pubmed-article:18544557 | pubmed:author | pubmed-author:PadayattyS... | lld:pubmed |
| pubmed-article:18544557 | pubmed:author | pubmed-author:RosadiukKK | lld:pubmed |
| pubmed-article:18544557 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18544557 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:18544557 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18544557 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18544557 | pubmed:pagination | 1969-74 | lld:pubmed |
| pubmed-article:18544557 | pubmed:dateRevised | 2009-2-17 | lld:pubmed |
| pubmed-article:18544557 | pubmed:meshHeading | pubmed-meshheading:18544557... | lld:pubmed |
| pubmed-article:18544557 | pubmed:meshHeading | pubmed-meshheading:18544557... | lld:pubmed |
| pubmed-article:18544557 | pubmed:meshHeading | pubmed-meshheading:18544557... | lld:pubmed |
| pubmed-article:18544557 | pubmed:meshHeading | pubmed-meshheading:18544557... | lld:pubmed |
| pubmed-article:18544557 | pubmed:meshHeading | pubmed-meshheading:18544557... | lld:pubmed |
| pubmed-article:18544557 | pubmed:meshHeading | pubmed-meshheading:18544557... | lld:pubmed |
| pubmed-article:18544557 | pubmed:meshHeading | pubmed-meshheading:18544557... | lld:pubmed |
| pubmed-article:18544557 | pubmed:meshHeading | pubmed-meshheading:18544557... | lld:pubmed |
| pubmed-article:18544557 | pubmed:meshHeading | pubmed-meshheading:18544557... | lld:pubmed |
| pubmed-article:18544557 | pubmed:meshHeading | pubmed-meshheading:18544557... | lld:pubmed |
| pubmed-article:18544557 | pubmed:meshHeading | pubmed-meshheading:18544557... | lld:pubmed |
| pubmed-article:18544557 | pubmed:meshHeading | pubmed-meshheading:18544557... | lld:pubmed |
| pubmed-article:18544557 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18544557 | pubmed:articleTitle | Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. | lld:pubmed |
| pubmed-article:18544557 | pubmed:affiliation | Montreal Centre for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research, McGill University and the Jewish General Hospital, Montreal, Quebec, Canada. l.hoffer@mcgill.ca | lld:pubmed |
| pubmed-article:18544557 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18544557 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:18544557 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18544557 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18544557 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18544557 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18544557 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18544557 | lld:pubmed |
